BioSpace News Archive

A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate’s possible return in relapsed/refractory multiple myeloma.

New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive results from an earlier trial.

Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.

Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a win in the race to get the first treatment to market for the condition.

While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further development of the program based on the totality of the data.

The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that it has finalized the development of an updated formulation of fostrox, suitable for commercial manufacture.

Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled “ Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity ”, during the World Vaccine Congress in Santa Clara, CA on November 28, 2023.

RVL Pharmaceuticals, Inc. announced that it and its wholly-owned U.S. operating subsidiary RVL Pharmacy, LLC, successfully emerged from their Chapter 11 cases on November 22, 2023 following the confirmation by the United States Bankruptcy Court for the District of Delaware of their Plan of Reorganization on November 20, 2023.